Efforts to improve clinical staging and identification of occult metastatic prostate cancer are instrumental in properly treating patients with prostate cancer. Currently, choosing the appropriate ...
LANGHORNE, Pa., Nov. 4 EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant ...
LANGHORNE, Pennsylvania and OXFORD, England, Nov. 3 /CNW/ - EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced ...
Patients with prostate cancer stand to benefit from new imaging techniques that ultimately allow for concentrated radiation therapy specific to the site of the cancer, part of a promising Mayo Clinic ...
Company says its Prostascint imaging agent for use in detecting prostate cancer increased the chances of survival and likelihood of being free of the disease.Princeton-based Cytogen (Nasdaq: CYTO), a ...
Aytu BioScience, Inc, a specialty healthcare company focused on developing treatments for urological and related conditions, has acquired Jazz Pharmaceuticals’ rights to ProstaScint, an imaging agent ...
STATEN ISLAND, N.Y. — In last week's article, I discussed transrectal ultrasound (TRUS) and prostate needle biopsy and how physicians use the Gleason score to grade prostate cancer. The focus today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback